SecBot SecBot
SECBOTREPLAY Home › Report › MNKD

MNKD · MannKind raised $50M via a private placement of 10.4M shares at…

MANNKIND CORP · 8-K filed Jul 24, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

8-K filed Jul 24, 2026 at 16:01 ET

MannKind raised $50M via a private placement of 10.4M shares at $3.89/share and 2.4M pre-funded warrants at $3.88/share, with proceeds earmarked for general corporate purposes including a $45M CVR payment triggered by the FDA approval of Furoscix ReadyFlow. The FDA approval of Furoscix ReadyFlow for edema in heart failure or chronic kidney disease is a significant regulatory milestone that validates the company's pipeline and triggers the CVR liability. The combination of dilutive financing to meet a known obligation and a major product approval creates a mixed picture: the approval is a clear positive catalyst, but the immediate need to raise capital at a discount to fund the associated CVR payment tempers the bullish sentiment and signals potential cash constraints.

  • MannKind raised $50.0 million in a private placement of 10,440,838 shares at $3.89/share and 2,412,632 pre-funded warrants at $3.88/share.
  • The FDA approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema in adults with heart failure or chronic kidney disease.
  • Net proceeds will fund general corporate purposes, including a $45.0 million contingent value rights (CVR) payment triggered by the FDA approval.
  • The private placement was led by Frazier Life Sciences, a longstanding biotech investment firm.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access